Valence

• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 5 High-risk Resected Melanoma
• Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled tr … Pending
  2024-514633-38-00 5 Crohn’s Disease
• FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending
  2024-514964-24-00 5 ulcerative colitis
• Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, doub … Pending
  2024-515663-59-00 5 intracerebral haemorrhage
• Efficacy of an empirical treatment with Amoxicillin-clavulanate (AC) compared to the combination Amoxicillin-clavulanate and Ciprofloxacin ( … Pending
  2025-520995-24-00 5 Adult patients treated for haematological disorders, in whom chemother
• Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt … Pending
  2025-521199-80-00 4 Patients with previously untreated symptomatic chronic lymphocytic leu
• Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR] Pending
  2025-522193-37-00 5 Septic arthritis
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn’s Disease : EMINENT CD Recruiting
  2025-521889-95-00 6 2026-05-04 Crohn's Disease
• PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai … Recruiting
  2025-522108-26-00 4 2026-02-19 métastatique colorectal cancer
• Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting
  2024-519971-25-00 5 2025-12-03 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
• Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting
  2024-515875-36-00 4 2025-08-18 Advanced biliary tract cancer (BTC)
• A multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BP1.4979 in adult p … Recruiting
  2024-517996-19-00 4 2025-06-19 Primary premature ejaculation
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 5 2024-06-24 Advanced Biliary Cancer (ABC)
• Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activi … Recruiting
  2023-508154-25-00 6 2024-05-27 Crohn's disease
• Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV … Recruiting
  2023-506232-32-00 9 2024-04-08 Multiple recurrences of Clostridioides difficile infection treated wit
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 9 2022-05-18 Low risk myelodysplastic syndrom without RS having failed or being ine
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting
  2023-508072-11-00 5 2019-06-26 Castration-resistant prostate cancer

Showing 1–24 of 45 trials